22 replies to this topic

[jandk]

THANKS for this GREAT Information-You too Trey!

[scuba]

http://phx.corporate...5076&highlight=

What about Ariad?

According to their own press release they cite that in some cases Major Molecular response occurred in less than two months.

Could Ariad be even better than Sprycell?

[Trey]

ARIAD AP24534 starts with a disadvantage since 94% of those on the study previously failed Gleevec and many also had failed a second TKI drug, and some have the T315i mutation.  So if it overcomes those issues, it should be a very good drug.

"responses to AP24534 are persistent and  include molecular responses in heavily pretreated patients with  resistant leukemia"

The full results will be withheld until the study is complete, so I would not jump to any conclusions comparing it to current drugs as a blanket statement, but it looks like the clinical trial is going well.  Also remember that side effects profiles will need to be compared to current drugs.  But if it helps with T315i, it is already going to be a major step forward since it will be the first targeted and oral drug for T315i when it comes to market (the Omapro will be an injected, non-targeted chemotherapy, when it is approved).  But remember that AP24534 is only in Phase I trials, so it has a long way to go (couple years).  Also, Dr Druker has a major role in the development program, so one would assume he would only be associated with a very good drug.